Pancreas Cancer Treatment

Pancreatic cancer (PC) represents one of the most lethal malignancies worldwide, currently ranking as the twelfth most commonly diagnosed cancer but the sixth leading cause of cancer-related death globally [1]. In 2022, an estimated 510,992 new cases and 467,409 deaths were attributed to the disease, with an overall five-year survival rate of approximately 10% [2]. Projections based on demographic aging and improved diagnostic access indicate that the global incidence may increase by approximately 95% by 2050, potentially reaching nearly 1 million new cases annually, with the steepest rises expected in regions undergoing rapid epidemiological transition [3].

Pancreatic cancer arises from the malignant transformation of cells within the exocrine or endocrine pancreas, with pancreatic ductal adenocarcinoma (PDAC) accounting for roughly 90% of all cases; the remaining fraction comprises neuroendocrine tumors, acinar cell carcinomas, and rarer histological subtypes [4]. Anatomically, approximately 75% of pancreatic carcinomas develop in the head or neck of the pancreas, 15–20% in the body, and 5–10% in the tail, a distribution that strongly influences clinical presentation [4]. Both modifiable and non-modifiable factors contribute to disease risk: cigarette smoking accounts for an estimated 25% of cases and roughly doubles individual risk, while obesity, long-standing type 2 diabetes mellitus, chronic pancreatitis, heavy alcohol consumption, and occupational exposure to certain industrial chemicals further increase susceptibility [5]. An inherited component is identified in 5–10% of patients, often associated with germline mutations in BRCA1/2, CDKN2A, STK11/LKB1, or mismatch repair genes [5].

Clinically, pancreatic cancer is dangerous not because it is rare, but because it is anatomically hidden and biologically silent. The pancreas lies deep in the retroperitoneum, behind the stomach, where small tumors produce no palpable mass and no early warning. Initial symptoms - vague epigastric discomfort, mild back pain, fatigue, or unexplained new-onset diabetes - are nonspecific and easily attributed to more benign conditions. By the time classical signs emerge, such as obstructive jaundice from biliary compression, significant weight loss, anorexia, or persistent pain radiating to the back, the tumor has frequently invaded local vasculature or seeded distant sites. Metastatic spread follows a characteristic anatomical logic: the liver is the most common first site, reached through the portal venous drainage of the pancreas, followed by the peritoneum, lungs, and less commonly bone, transforming a focal pancreatic lesion into a rapidly progressive systemic disease.

Use as you wish

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022:

[2] Ilic I, Ilic M. International patterns and trends in the incidence and mortality of pancreatic cancer

[3] Huang J, et al. Global, regional, and national burden of pancreatic cancer and its attributable risk factors from 2019 to 2021, with projection to 2044.

[4] Hu JX, Zhao CF, Chen WB, et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors.

[5] Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors.